Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CMS D002

Next Previous
Drug Profile

CMS D002

Alternative Names: CMS-D002

Latest Information Update: 01 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator China Medical System
  • Class
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Uterine leiomyoma

Most Recent Events

  • 26 Aug 2026 Shenzhen Kangzhe Biotechnology plans a phase-I pharmacokinetics trial (In volunteers) in China (PO) in September 2026 (NCT07788482)
  • 09 Jan 2026 Phase-II clinical trials in Uterine leiomyoma in China (PO) (NCT07402369)
  • 21 Sep 2022 Preclinical trials in Female genital diseases in China (unspecified route) (China Medical System pipeline, September 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top